MedTrace Logo

Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia

NCT02206243 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-06-14

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the prostatic arterial embolization (PAE) with Embozene® Microspheres (Boston Scientific) in sphere sizes of 250 µm for the treatment of symptomatic benign prostatic hyperplasia (BPH).

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

Embozene Microspheres

Intraarterial application

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Ulf Teichgräber, Prof. · Institute of Diagnostic and Interventional Radiology

  • Marc-Oliver Grimm, Prof. · Department of Urology

  • Tobias Franiel, Dr. med. · Institute of Diagnostic and Interventional Radiology

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-11-30
Completion
2019-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206243 on ClinicalTrials.gov